{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:44:43Z","timestamp":1773035083532,"version":"3.50.1"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>The risk of viral infections and reactivation occurring in the setting of pediatric allogeneic hematopoietic stem cell transplantation is a concern in the pediatric patient, especially with the use of Alemtuzumab (Campath) as a conditioning agent. The purpose of this study was to determine the incidence of Epstein-Barr virus posttransplant lymphoproliferative disorder (EBV-PTLD), cytomegalovirus (CMV), and adenovirus among pediatric recipients of alemtuzumab at our institution. We found that EBV-PTLD occurred in 2.1% of transplants (1 matched unrelated donor [MUD] recipient), CMV reactivation occurred in 12.5% of transplants (4 MUD and 2 matched related donor [MRD] recipients) with disseminated CMV in 2.1% of cases (1 MRD recipient), and adenovirus infection occurred in 8.3% of the total transplants (2 MUD and 2 MRD recipients). Alemtuzumab continues to be used as a method of graft-versus-host disease and graft failure prevention among pediatric recipients of hematopoietic stem cell transplantation and seems to be safer than previously reported. At our institution, alemtuzumab has not increased the risk for EBV-PTLD, CMV infection, or adenovirus.<\/jats:p>","DOI":"10.1097\/mph.0000000000001138","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T16:17:18Z","timestamp":1522858638000},"page":"e473-e478","source":"Crossref","is-referenced-by-count":8,"title":["EBV-PTLD, Adenovirus, and CMV in Pediatric Allogeneic Transplants With Alemtuzumab as Part of Pretransplant Conditioning: A Retrospective Single Center Study"],"prefix":"10.1097","volume":"40","author":[{"given":"Margaret C.","family":"Cupit-Link","sequence":"first","affiliation":[{"name":"Mayo Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amulya","family":"Nageswara Rao","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti M.","family":"Warad","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilmarie","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakila","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath-1H antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejphar.2005.03.024","article-title":"Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity","volume":"514","author":"Nuckel","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.bmt.1702477","article-title":"CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells","volume":"26","author":"Hale","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MPH.0b013e31822ec296","article-title":"Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience","volume":"34","author":"Nageswara Rao","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/14737140.5.1.39","article-title":"Alemtuzumab","volume":"5","author":"Ravandi","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.immunol.15.1.405","article-title":"Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection","volume":"15","author":"Rickinson","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MPH.0b013e3181ed336f","article-title":"Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia","volume":"33","author":"Ruf","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bmt.2013.96","article-title":"EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT","volume":"49","author":"Rasche","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/10428190601059837","article-title":"EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning","volume":"48","author":"Cohen","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood.V71.5.1234.1234","article-title":"Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation","volume":"71","author":"Shapiro","year":"1988","journal-title":"Blood"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00838047","article-title":"Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)","volume":"20","author":"Nalesnik","year":"1998","journal-title":"Springer Semin Immunopathol"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.bbmt.2016.04.004","article-title":"Cytomegalovirus infection in pediatric hematopoietic stem cell transplantation: risk factors for primary infection and cases of recurrent and late infection at a single center","volume":"22","author":"Rowe","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1086\/429235","article-title":"Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary?","volume":"40","author":"Walls","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/infdis\/169.4.775","article-title":"Increasing incidence of adenovirus disease in bone marrow transplant recipients","volume":"169","author":"Flomenberg","year":"1994","journal-title":"J Infect Dis"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/sj.bmt.1702716","article-title":"Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation","volume":"26","author":"Baldwin","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1086\/341770","article-title":"High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation","volume":"35","author":"Schilham","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1083-8791(03)00102-2","article-title":"Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival","volume":"9","author":"Bruno","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bmt.1701563","article-title":"Adenovirus infection after pediatric bone marrow transplantation","volume":"23","author":"Hale","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.bbmt.2013.09.001","article-title":"An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis","volume":"19","author":"Marsh","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","article-title":"In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation","volume":"96","author":"Kottaridis","year":"2000","journal-title":"Blood"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.bmt.1701468","article-title":"Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience","volume":"22","author":"Micallef","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.V78.8.2139.2139","article-title":"Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies","volume":"78","author":"Antin","year":"1991","journal-title":"Blood"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pbc.20604","article-title":"The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?","volume":"47","author":"Greenfield","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2008.08.010","article-title":"Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen","volume":"14","author":"Kennedy-Nasser","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1365-2141.2001.03087.x","article-title":"Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation","volume":"115","author":"Hoshino","year":"2001","journal-title":"Br J Haematol"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V98.4.972","article-title":"Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell\u2013depleted SCT","volume":"98","author":"van Esser","year":"2001","journal-title":"Blood"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/JCM.40.2.351-358.2002","article-title":"Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease","volume":"40","author":"G\u00e4rtner","year":"2002","journal-title":"J Clin Microbiol"},{"key":"R29-20230918","first-page":"e2009019","article-title":"Epstein-Barr virus related lymphoproliferations after stem cell transplantation","volume":"1","author":"Sica","year":"2009","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R30-20230918","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/bmt.2008.149","article-title":"Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab","volume":"42","author":"Bokhari","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1399-3062.2009.00411.x","article-title":"Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases","volume":"11","author":"Styczynski","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood.V95.4.1502.004k40_1502_1505","article-title":"CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation","volume":"95","author":"Kuehnle","year":"2000","journal-title":"Blood"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2141.2001.03041.x","article-title":"Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children","volume":"115","author":"Faye","year":"2001","journal-title":"Br J Haematol"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-6143.2005.01211.x","article-title":"Treatment of PTLD with rituximab or chemotherapy","volume":"6","author":"Elstrom","year":"2006","journal-title":"Am J Transplant"},{"key":"R36-20230918","first-page":"1248","article-title":"Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir","volume":"89","author":"Laurenti","year":"2004","journal-title":"Haematologica"},{"key":"R37-20230918","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3816\/CLM.2002.n.016","article-title":"Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"3","author":"Nguyen","year":"2002","journal-title":"Clin Lymphoma"},{"key":"R38-20230918","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ehm.10.77","article-title":"Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab","volume":"4","author":"Vallejo","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbmt.2003.12.169","article-title":"Cytomegalovirus (CMV) infection in patients receiving either alemtuzumab (CAMPATH 1-H) or antithymocyte globulin (ATG) as graft-versus-host disease (GVHD) prophylaxis prior to allogeneic stem cell transplantation (SCT)","volume":"10","author":"Hunt","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"R40-20230918","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"R41-20230918","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1705249","article-title":"Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning","volume":"37","author":"Kline","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R42-20230918","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","article-title":"Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy","volume":"111","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"R43-20230918","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1080\/10428190600929311","article-title":"An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab","volume":"47","author":"Visani","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R44-20230918","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1016\/j.bbmt.2014.11.326","article-title":"Serotherapy with alemtuzumab but not ATG is associated with increased adenovirus infection in pediatric recipients of cord blood grafts","volume":"21","author":"Chaudhry","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R45-20230918","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bmt.1705164","article-title":"Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)","volume":"36","author":"Myers","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R46-20230918","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2002-02-0377","article-title":"Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery","volume":"100","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"R47-20230918","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbmt.2003.11.001","article-title":"Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab","volume":"10","author":"Avivi","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"R48-20230918","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9343(97)00015-6","article-title":"Adenovirus infections in immunocompromised patients","volume":"102","author":"Carrigan","year":"1997","journal-title":"Am J Med"},{"key":"R49-20230918","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1086\/498151","article-title":"Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients","volume":"41","author":"Muller","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R50-20230918","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/319984","article-title":"Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Bordigoni","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R51-20230918","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/blood.V86.10.3979.bloodjournal86103979","article-title":"Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients","volume":"86","author":"Ochs","year":"1995","journal-title":"Blood"},{"key":"R52-20230918","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199708073370602","article-title":"Outcome of Cord-Blood Transplantation from Related and Unrelated Donors","volume":"337","author":"Gluckman","year":"1997","journal-title":"N Engl J Med"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201811000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:09:48Z","timestamp":1695010188000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201811000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001138","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}